Barclays Lifts Target on Alexion Pharmaceuticals (ALNX) After Adding NMO Into Model

Barclays boosted its price target on Overweight-rated Alexion Pharmaceuticals (NASDAQ: ALXN) from $112 to $120.

The firm expects Soliris clinical data in NMO to be presented at the annual American Neurological Association meeting held October 7-9 in Boston... "we believe Soliris should prove efficacious in severe NMO patients in the upcoming results of the Phase II trial. They see NMO as an attractive commercial opportunity with estimated peak sales of $780 million. Inclusion of NMO into their model adds $8 per share to their price target.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $110.46 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities